Browse the evidence

Tirzepatide treatment (10-15 mg once weekly) significantly improves waist-to-height ratio (WHtR) categories compared to placebo, with 54.7% of participants improving their WHtR category at 72 weeks versus 9.6% on placebo.

If you have obesity or overweight with related health complications, treatment with tirzepatide (10-15 mg weekly) combined with lifestyle changes significantly improves your waist-to-height ratio, a key marker for cardiometabolic risk, far more effectively than placebo. This suggests a substantial reduction in central adiposity.

Tirzepatide produced a mean weight loss of −7.14 kg in individuals without diabetes and −5.87 kg in individuals with type 2 diabetes (T2D).

Tirzepatide may be an effective option for weight management in both diabetic and non-diabetic obese adults.

Supplementation with Vicia faba protein hydrolysate (VFH) at a low dose of 2.4g/day significantly enhances leg strength and muscular endurance beyond resistance training alone in healthy, untrained adults.

Take 2.4g of Vicia faba protein hydrolysate daily with your first meal while doing resistance training 3 times a week. This specific supplement has been shown to improve leg strength and endurance more than training alone, even without increasing your total protein intake.

Vicia faba protein hydrolysate (VFH) supplementation significantly increases Bone Mineral Content (BMC) compared to placebo when combined with resistance training.

If you are concerned about bone health, this specific supplement taken with resistance training may help increase bone mineral content, showing a 0.7% increase over 8 weeks.

Significant weight loss achieved through intensive lifestyle interventions, low-calorie diets, metabolic surgery, or GLP-1-based medications can induce remission of type 2 diabetes, particularly in patients with short disease duration and younger age.

If you have recently been diagnosed with Type 2 diabetes, aggressive weight loss through diet, surgery, or GLP-1 medications can potentially put your diabetes into remission, allowing you to stop medication. This is most effective if you act early, lose a significant amount of weight (10-15kg+), and maintain it. Consult your doctor about remission protocols like the DiRECT study's low-calorie diet or GLP-1 therapies.

Structured physical activity of at least 150 minutes per week significantly reduces HbA1c levels in individuals with Type 2 diabetes.

Aim for at least 150 minutes of moderate aerobic exercise (like brisk walking or cycling) every week. If time is tight, try High-Intensity Interval Training (HIIT) for shorter, effective sessions. Consistency matters more than intensity for long-term glucose control.

GLP-1 receptor agonists (e.g., Semaglutide, Liraglutide) and SGLT-2 inhibitors improve glycemic control, body weight, and cardiovascular risk factors in obese patients with type 2 diabetes.

If lifestyle changes alone are insufficient, medications like GLP-1 agonists (e.g., Semaglutide) or SGLT-2 inhibitors can help manage blood sugar and support weight loss. These are prescribed when lifestyle interventions fail to meet targets.

Exercise alleviates chronic pain through neuroplasticity, endorphin release, and anti-inflammatory myokine secretion.

Regular exercise changes how your brain processes pain and releases natural painkillers (endorphins) and anti-inflammatory chemicals (myokines) from your muscles, helping you tolerate pain better.

Low-glycemic index diets improve insulin sensitivity and glycemic control, primarily through weight loss and reduced postprandial glucose spikes.

Focus on choosing carbohydrates with a lower glycemic index, such as whole grains, legumes, and vegetables. This can help manage blood sugar spikes and support weight loss. Remember that overall diet quality and fiber intake are also important.

Post-bariatric recurrent weight gain (RWG) can be effectively managed with FDA-approved anti-obesity medications (AOMs) such as GLP-1 receptor agonists (liraglutide, semaglutide), phentermine/topiramate, naltrexone/bupropion, and orlistat, which reduce weight regain or aid weight loss.

If you are gaining weight back after bariatric surgery, talk to your doctor about FDA-approved anti-obesity medications. Drugs like semaglutide (Ozempic/Wegovy) or liraglutide (Saxenda) are specifically approved and shown to help with weight loss and preventing regain. They work by affecting hormones that control hunger and stomach emptying. While they involve injections and can cause nausea, they are a potent tool to avoid more complex revisional surgeries.

Post-bariatric recurrent weight gain (RWG) can be managed with other FDA-approved anti-obesity medications including phentermine/topiramate, naltrexone/bupropion, and orlistat, which reduce weight regain or aid weight loss.

If GLP-1 injections are not suitable or effective for your post-surgery weight regain, ask your doctor about other FDA-approved oral medications. Options include phentermine/topiramate, naltrexone/bupropion, and orlistat. These drugs have different mechanisms and side effect profiles, so your doctor can help you choose the best fit. They are proven to help with weight loss and managing RWG.

Focusing on carbohydrate quality (high fiber, low glycemic load) is more effective for obesity management than restricting carbohydrate quantity (low-carb diets).

Prioritize the type of carbohydrates you eat over the amount. Choose whole grains, legumes, and fruits that are high in fiber and have a low glycemic impact. This approach supports better metabolic health and weight management compared to simply cutting out carbs.

Soy protein promotes gains in muscle mass and strength during resistance exercise training similarly to whey and other animal proteins, despite acute studies showing whey stimulates muscle protein synthesis more strongly.

If you are lifting weights, you do not need to buy whey protein. Soy protein works just as well for building muscle and strength over time. Focus on getting enough total protein from your diet, whether from soy, meat, or other sources.

Early combination therapy with new hypoglycemic drugs (SGLT-2i, GLP-1RA, or DPP-4i) achieves glycemic control faster and provides longer-lasting benefits compared to traditional stepwise monotherapy in prediabetes and type 2 diabetes.

If you have Type 2 Diabetes or prediabetes, starting with a combination of modern drugs (like SGLT-2 inhibitors, GLP-1 agonists, or DPP-4 inhibitors) alongside metformin is often more effective than starting with just one drug. This approach helps you reach healthy blood sugar levels faster and keeps them there longer, reducing the need to change treatments frequently. Discuss this strategy with your doctor to see if it fits your specific health profile and insurance coverage.

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) and SGLT-2 inhibitors are preferred medications for obesity management in patients with cardiovascular or metabolic risk, as they promote weight loss and improve cardiovascular health.

If you have obesity and diabetes or heart disease risk, ask your doctor about GLP-1 agonists (like semaglutide) or SGLT-2 inhibitors. These medications help you lose weight and protect your heart, unlike some other diabetes drugs that might cause weight gain.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide and tirzepatide are effective for weight loss in people with HIV, with tirzepatide showing the largest mean percent change in weight.

If lifestyle changes are not enough to manage weight gain from HIV medication, ask your doctor about GLP-1 RAs like semaglutide or tirzepatide. These drugs are highly effective for weight loss and can help reduce fat deposits. They are used alongside diet and exercise.

GLP-1 receptor agonists (semaglutide 2.4 mg) and other pharmacological interventions (liraglutide, orlistat) significantly reduce body weight and cardiovascular risk factors in obese patients, with semaglutide showing superior weight loss compared to placebo.

For obese individuals without diabetes, high-dose semaglutide (2.4 mg) can achieve substantial weight loss (approx. 15%) compared to placebo, which may improve cardiovascular risk factors. This is a viable option when lifestyle changes are insufficient.

Moderate-to-vigorous physical activity (MVPA) performed during morning hours (06:00–12:00) significantly reduces the risk of developing diabetic retinopathy (DR) and slows retinal thinning, whereas late-night physical activity increases DR risk.

If you have diabetes or are at risk, aim for at least 150 minutes of moderate-to-vigorous exercise per week. Crucially, try to schedule these workouts in the morning (between 6 AM and 12 PM). This timing appears to offer the strongest protection against diabetic eye disease. Avoid exercising late at night (midnight to 6 AM), as this may increase your risk.

Consuming grain foods that meet a carbohydrate-to-fiber ratio of ≤10:1 is associated with significantly lower levels of cardiometabolic risk factors, specifically triacylglycerols, the triacylglycerol/HDL-c ratio, fasting insulin, and HOMA-IR.

To improve insulin sensitivity and lipid profiles, prioritize grain foods that have a carbohydrate-to-fiber ratio of 10:1 or lower. This means for every 10 grams of carbohydrates, there should be at least 1 gram of fiber. Replacing white rice and white bread with brown rice and whole wheat bread (which typically meet this ratio) significantly increases fiber, magnesium, and zinc intake while reducing total carbohydrates and added sugars.

Tirzepatide (10 mg and 15 mg) achieves statistically equivalent total body weight loss to sleeve gastrectomy (SG), with both interventions demonstrating superior efficacy compared to other pharmacotherapies.

If you are an adult with obesity, high-dose Tirzepatide (10-15 mg weekly) can help you lose approximately 21% of your body weight, which is statistically the same amount of weight loss achieved by sleeve gastrectomy surgery. This makes it a highly effective non-surgical option, though it requires weekly injections and lifestyle modifications.

Patients with prediabetes or drug-naive type 2 diabetes achieve significantly higher odds of substantial weight loss (≥10%) with Gelesis100 compared to placebo.

If you have prediabetes or early type 2 diabetes, Gelesis100 may be particularly effective for you, offering much higher odds of losing 10% or more of your body weight compared to those with normal blood sugar.

Once-daily oral semaglutide 50 mg significantly reduces ad libitum energy intake, body weight, and appetite while improving control of eating in adults with obesity, without delaying gastric emptying at steady state.

Take oral semaglutide 50 mg once daily, following the specific dose-escalation schedule (starting at 1.5 mg and increasing every 4 weeks). Do not eat or drink (except water) for 6 hours before taking the tablet, and wait 30-45 minutes after taking it before your first meal. This regimen significantly reduces your energy intake and body weight primarily by lowering appetite and improving control over eating, rather than by slowing down your digestion.

A multi-component intervention (SAMMAS) combining low-carbohydrate nutrition (≤30% carbs), meal replacement, continuous glucose monitoring, and telemedical coaching significantly reduces body weight and fasting insulin in overweight/obese adults compared to a control group, with effects sustained at 52 weeks.

To lose weight and improve metabolic health, consider a structured program that combines a low-carbohydrate diet (limiting carbs to 30% or less of calories), potentially using meal replacement formulas for some meals, and leveraging technology like glucose monitors and coaching for accountability. This approach targets insulin levels to facilitate fat loss, rather than relying solely on calorie counting.

Tirzepatide (5, 10, and 15 mg once weekly) produces significantly greater weight loss than both placebo and GLP-1 receptor agonists (semaglutide, dulaglutide) in adults with overweight or obesity.

If you have overweight or obesity, tirzepatide (administered once weekly) is a highly effective pharmacological option for weight loss, outperforming both placebo and existing GLP-1 medications like semaglutide. Expect significant weight reduction (up to ~12.5 kg with the highest dose) and a higher likelihood of achieving major weight loss milestones (5%, 10%, 15%). Be prepared for potential gastrointestinal side effects (nausea, diarrhea), which are common but often manageable and comparable to other drugs in this class. Consult a healthcare provider to determine if you are a candidate based on your BMI and health status.